Viridian Therapeutics Revenue and Competitors

Boulder, CO USA

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Viridian Therapeutics's estimated annual revenue is currently $23.4M per year.(i)
  • Viridian Therapeutics's estimated revenue per employee is $155,000

Employee Data

  • Viridian Therapeutics has 151 Employees.(i)
  • Viridian Therapeutics grew their employee count by 30% last year.

Viridian Therapeutics's People

NameTitleEmail/Phone
1
Director, Competitor InsightsReveal Email/Phone
2
Senior DirectorReveal Email/Phone
3
Project Manager CMCReveal Email/Phone
4
Project ManagerReveal Email/Phone
5
Project CoordinatorReveal Email/Phone
6
Senior ScientistReveal Email/Phone
7
Senior Research AssociateReveal Email/Phone
8
CMC CoordinatorReveal Email/Phone
9
Senior ScientistReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$1.7M110%N/AN/A
#2
$2.8M1813%N/AN/A
#3
$70.2M453-1%N/AN/A
#4
$1.6M10-66%N/AN/A
#5
$3.7M24-8%N/AN/A
#6
$2.9M3728%N/AN/A
#7
$3.1M2025%N/AN/A
#8
$2.5M16-20%N/AN/A
#9
$9.1M590%N/AN/A
#10
$4.2M27-7%N/AN/A
Add Company

What Is Viridian Therapeutics?

Viridian Therapeutics is a biotechnology company advancing new treatments for patients suffering from serious diseases but underserved by today's therapies. Viridian's most advanced program, VRDN-001, is a clinical-stage anti-IGF-1R monoclonal antibody in development for thyroid eye disease (TED). Viridian is headquartered in Boulder, Colo., with research and development operations in Waltham, Mass.

keywords:N/A

N/A

Total Funding

151

Number of Employees

$23.4M

Revenue (est)

30%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Viridian Therapeutics News

2022-04-17 - Comparing Sera Prognostics (NASDAQ:SERA) & Viridian ...

This table compares Sera Prognostics and Viridian Therapeutics' revenue, earnings per share and valuation. Gross Revenue, Price/Sales Ratio, Net...

2022-04-13 - Viridian Therapeutics, Inc. (NASDAQ:VRDN) Given Average ...

Viridian Therapeutics, Inc. (NASDAQ:VRDN) Given Average Recommendation of “Buy” by Analysts. Posted by admin on Apr 12th, 2022.

2022-03-30 - Viridian Therapeutics Secures Flexible Credit Facility for Up to ...

Viridian Therapeutics is a biotechnology company advancing new treatments for patients suffering from serious diseases but underserved by...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$37.9M1512%N/A
#2
$38.4M153-1%N/A
#3
$42.5M1544%N/A
#4
$25.5M160-20%N/A
#5
$31.9M1616%N/A